Product logins

Find logins to all Clarivate products below.


Pancreatic Cancer | Niche Disease Landscape & Forecast | G7 | 2016

Pancreatic cancer remains a deadly disease with limited treatment options. The current standards of treatment are mFOLFIRINOX and gemcitabine + Abraxane. Market growth over the forecast period to 2020 will be driven by the premium-priced products Abraxane and Onivyde and then, over the five years to 2025, by the new product introductions of Lynparza and PEGPH20. Longer-term promise lies in emerging dual and multiple combinations of targeted agents, particularly the PD-1 and PD-L1 checkpoint inhibitors.

Related Market Assessment Reports

Report
Pancreatic Cancer – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of pancreatic cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the incidence of pancreatic cancer for…
Report
Pancreatic Cancer – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of pancreatic cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…
Report
Pancreatic Cancer – Epidemiology – Extrapolated Worldwide Coverage
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key pancreatic cancer patient populations, covering 171 countries and…
Report
Pancreatic Cancer – Unmet Need – Unmet Need – Locally Advanced or Metastatic Pancreatic Adenocarcinoma (US/EU)
Pancreatic adenocarcinoma is an aggressive malignancy associated with an extremely poor prognosis and high lethality. The metastatic setting is the largest drug-treatable population in pancreatic…
Report
Pancreatic Cancer – Landscape & Forecast – Disease Landscape & Forecast
Pancreatic cancer is a notoriously aggressive and hard-to-treat malignancy; the five-year survival rate is around 10%. Treatment options for pancreatic cancer are limited to surgery, radiation, and…